Rexon-Eye

Rexon-Eye® stands out as a groundbreaking, non-invasive solution for various treatments of dry eye syndromes.

Rexon-Eye®

  • Effective therapy for all types of the dry eye disease, evaporative, aqueous deficient and mixed dry eye.
  • Long term benefits starting along or just after the treatment.
  • Comfortable, pleasant and relaxing treatment for the patient.
  • Stimulates regeneration of tissues and cells.
  • Reduces inflammation.

REVOLUTIONIZING DRY EYE TREATMENT

This device employs low-power, high- frequency electric fields to stimulate cellular metabolism and natural regeneration, targeting the root cause of dry eye disease.

Its effectiveness spans across the spectrum of dry eye conditions, including both evaporative and aqueous deficient types, with its efficacy well-documented through numerous subjective and objective studies.

Rexon-Eye TREATMENT

The treatment is delivered by contact electrodes built into a mask, which is worn by the patient over closed eyes. The device setup is very easy and intuitive.

For a successful treatment, set aside a quiet area and create a relaxed atmosphere to ensure optimal result.

REGENERATIVE TECHNOLOGY

The principle of operation of Rexon-Eye® is the QMR® technology, which delivers a weak alternate electrical current containing a specific mix of frequencies (from 4 MHz to 64 MHz) that has been shown to stimulate the natural regeneration of cells, in addition to having an important anti-inflammatory action.

ANTI-INFLAMMATORY EFFECT

QMR® technology effectively disrupts the vicious cycle of dry eye by exerting a potent anti-inflammatory effect. It modulates macrophage polarization, shifting from a pro-inflammatory state to an anti-inflammatory one, thereby reducing inflammation and stabilizing the tear film.

4

TREATMENT SESSIONS

20

MINUTES EACH

1

WEEK INTERVAL

Rexon-Eye is currently patented in Europe, China, US, Russia, South Africa, Australia, Korea, and is pending in other countries.

The device is present in the National List of Medical Devices of the Italian Ministry of Health as a Class IIa device in the CND ‘Instrumentation for therapeutic and surgical treatments in ophthalmology.’

In 2016, Rexon-Eye obtained the EC certification mark as a ‘Medical device for the treatment of ocular surface disorders’ and, in 2018, after further clinical studies, it entered the therapeutic devices market.

Resono Ophthalmic is the only company in the world that applies the revolutionary QMR ® technology to the treatment of ophthalmic diseases, which has proven to be able to provide significant benefits to patients with dry eye disease.

It is, therefore, appropriate to briefly introduce some basic aspects of this technology.

Electricity and the human body

It has been known for centuries that electric currents flow throughout our body and carry the signals necessary for its operation.

The heart and muscles in general contract because they are stimulated by an electric current, just as the eyes and ears allow us to see and hear because they generate and transmit electrical signals to our brain.

These electrical stimuli are generated by the body itself, but others may be artificially generated and applied by biomedical tools designed for this purpose.

Electric currents and regenerative processes

It was recently discovered that electrial signals are able to interact with the regulation of cell behavior and homeostasis of tissues (read the paper); phenomena that are the basis of many healing processes. (read the paper)

The main difficulty of artificial stimulation is to be able to generate the correct signals, that is, those able to interact with the organism to stimulate regenerative processes.

Discovery of the QMR effect

Research activities aimed at making a surgical cut without a temperature increase, conducted at the company, Telea Medical, led to the discovery of a physical effect called Quantum Molecular Resonance (QMR)*, in which an alternating electrical signal containing a specific frequency range, from 4 to 16 MHz, appears to be in resonance, that is, it has the same frequency as the oscillations of molecular bonds in biological tissues.

This particular situation allows for maximizing the transfer of energy from the electrical stimulus signal to the biological tissue, with a minimum dispersion in heat and, therefore, maximum efficiency in opening the molecular bonds (see on the right an image of the perfect cut obtained).

* QMR is a registered trademark of Telea Medical.

This discovery was originally used by the company to develop a revolutionary cold electro-scalpel (read the paper), which allows for obtaining a surgical cut effect without raising the temperature of tissues.

It is a highly innovative electro-scalpel, which allows for significant benefits for the patient and surgical procedures in very delicate areas of the body, such as the brain and nerve endings.

QMR for tissue regeneration

In subsequent experiments, it was discovered that an alternating electrical signal with an even wider frequency range (from 4 to 64 MHz) is able to obtain another significant effect, namely, precisely the stimulation of metabolism and natural regeneration of biological tissues and cells.

Various phenomena observed experimentally can explain this effect: the mechanical deformation of the cell membrane, the increase in calcium release, and the stimulation of metabolism (read the paper).

Using sophisticated analysis techniques (DNA micro-array), a recent study on cells treated with QMR has experimentally demonstrated its ability to stimulate the over-expression of some genes involved in the natural tissue regeneration processes (read the paper).

This new discovery paved the way for the application of QMR to various areas of medicine, such as aesthetic medicine, pain management medicine, and physiotherapy.

In this regard, it is interesting to point out the significant results obtained by QMR stimulation in healing deep wounds in the limbs, also for their potential application to healing corneal wounds (read the paper).

Rexon-Eye field of application

The Rexon-Eye device currently finds its main application in the treatment of dry eye (DE), a complex pathology due to trauma, inflammation, deficit, infection, or other, which causes abnormalities of the ocular surface and eyelids, and in the composition of the tear film, with significant repercussions on vision.

Rexon-Eye, unique in the therapeutic device landscape, is successfully used in all DE patients, whether they are hyposecretive (“aqueous deficient”, ADDE), evaporative (EDE), or mixed.

The Rexon-Eye Difference

Compared to other devices on the market that often simply warm the treated area and are only able to alleviate symptoms of the disease, Rexon-Eye applies a treatment capable of stimulating recovery of normal function of the organs involved.

The hypothesis behind these benefits is that the QMR signal applied by the device stimulates the natural regeneration of the lacrimal system of patients, reactivating glandular tissue and physiological tear secretion, and thus providing functional benefits to the entire lacrimal functional unit.

26 subjects, with evaporative or hyposecretive DE, were treated and then examined up to one year from the end of the treatment.

An important aspect of this study is the confirmation of the long-term benefits of Rexon-Eye treatment: some of the measured parameters were still improving at the end of the one-year observation period. The results of the study are reported in a work published in the British Journal of Ophthalmology, to which reference may be made for further information.

FIND OUT MORE

25 subjects, all affected by Evaporative DE (Meibomian Gland Disease, MGD), were treated with Rexon-Eye.

In this specific type of DE, it is important to evaluate the benefit obtained on the functionality of the Meibomian glands, which are responsible for generating the lipid substance that limits tear evaporation. The parameters measured to characterize this specific functionality, relating to the quantity and quality of the secretion, showed a significant improvement after treatment with Rexon-Eye.

The results of the study are reported in a work published in Cornea, to which reference may be made for further information.

FIND OUT MORE

9 subjects, affected by an advanced mixed form of DE (both evaporative and hyposecretive), were treated with Rexon-Eye.

In this particularly difficult to treat patient group, the measured parameters also showed significant improvement after treatment with Rexon-Eye.

The results of the study are reported in the ARVO 2020 congress proceedings, to which reference may be made for further information.

FIND OUT MORE

9 subjects, affected by an advanced mixed form of DE (both evaporative and hyposecretive), were treated with Rexon-Eye.

In this particularly difficult to treat patient group, the measured parameters also showed significant improvement after treatment with Rexon-Eye.

The results of the study are reported in the ARVO 2020 congress proceedings, to which reference may be made for further information.

FIND OUT MORE

Tips for optimal treatment with Rexon-Eye®

It is well known that dry eye is a multifactorial disease.

Alongside a pathological or genetic basis, the incidence of environmental and psychophysical factors on the severity of symptoms is well known.

That’s why with a regenerative therapy such as Rexon-Eye®, we believe it is necessary to create the best environmental conditions for the success of the treatment.

Although many patients report an immediate benefit just after the first session, the action of Rexon-Eye® requires a physiological time for reactivating the cells and the body as well needs to be prepared for the healing process, to obtain effective and long-lasting results.

Therefore we believe that a relaxed atmosphere in a reserved and calm place is a key factor in ensuring your patients the maximum results from the treatment.

In this page, we’ve gathered some tips and useful information to create the most suitable environment for the treatment.

Main aspects of the treatment

Rexon-Eye® is a non-invasive therapy that does not cause any pain or discomfort. It does not require analgesics or cooling systems on the skin (e.g., gel).

During the treatment, patients only experience a slight and pleasant sensation of warmth underneath the mask.

Resono Ophthalmic is not aware of any trauma or physical damage that may be caused by the Rexon-Eye® usage.

Patients excluded from the treatment:

  • pregnant women
  • patients with implanted active medical devices (e.g., pacemakers or hearing aids)
  • infants or children (under 18 years)
  • patients undertaking cancer therapy
  • patients who underwent ocular surgery in the last month

The recommended treatment consists of

4 session

20 minutes each

1 week break

To create a well-being environment

We suggest setting up in your clinic a special area reserved for the treatment, following these indications:

  • find a space suitable for the Rexon-Eye® treatment, quiet and possibly isolated from the other activities of the clinic
  • use for treatment a comfortable reclining chair, where the patient may feel relaxed
  • ensure warm lighting with a soft and wide shade

Before starting the treatment

  • Make sure to place the mask with uniform contact over the eyes, without exerting high pressure
  • Lower the brightness of the light sources

Treatment delivery strips

Rexon-Eye must be used with special disposable waterproof facial strips, worn between the mask electrode and the eyelid surface.

These strips help to uniformly spread the electrical current over the whole eye surface, increasing its capability to reach Meibomian and lacrimal glands on the patients. Moreover, the electrical properties of their fabric allow minimizing the current intensity capable to elicit the QMR® therapeutic effect.

They also play an essential role in assuring patient personal hygiene, by avoiding bacteria and virus transmission.

LEARN MORE

Within this environment, the session can be even more pleasant and relaxing with some simple expedients

Download the treatment leaflet for the patient

Technical data

  • Technical data
  • LCD display
  • Supply Voltage and frequency: 100-230V ~ 50 / 60Hz
  • Maximum Power Consumption: 300VA
  • Maximum output power: 40W / 200 Ω dual channel (mask)
  • Weight: 8kg
  • Dimensions: 40x18x35 cm
  • Output Frequency: frequency spectrum between 4MHz and 64MHz (patented spectrum)
  • Rexon-Eye is classified Class IIa According to Annex 9 of Directive 93/42 /EEC and s.m.i. (2007/47/EC)

Rexon-Eye is covered by patent in Europe EP3349848A1, USA US 10,376,691 B2, Russia RU2723113, Korea KR 10-2183930 and Australia 2016344594. Patents pending in several other countries.

Who we are

How Rexon-Eye works

Rexon-Eye first tutorial by Resono

Luca Vigo, head of Dry Eye Center (CARONES Vision) about Rexon-Eye device

Interview with Alfredo Ruggeri, Chairman of Resono Ophthalmic company

REXON EYE Vietnam webinar 2021 07 23

Rexon-eye Brochure
Download PDF

Flyer Rexon-Eye
Download PDF

Patient Brochure
Download PDF

Ask for Tech Support

MORE INFO

Request a Quote

QUOTE